KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Inte...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 18, 2024

Targeting A Solution Panel Aims to Find Solutions for the Veteran Suicide Crisis with National Thought Leaders Tulsi Gabbard, Ti • Wheels in Motion: Nationwide Ride of a Life Time Cycling Event Set for April 27 to Support Children's Health • Angels Helpers NYC Announces 2024 Charity Gala “Big City, Big Hearts: New Yorkers Helping New Yorkers” • Semrush Holdings, Inc. Announces Investor Conference Call to Review First Quarter 2024 Financial Results • Sundial Media Group Extends Its Reach, Further Diversifying the Media Landscape • SuperWomen Of FMS Leadership Award Nominations Now Open • Bright Horizons Family Solutions Announces Date of First Quarter 2024 Earnings Release and Conference Call • First Annual U.S.-Ukraine Veterans' Charity Golf Tournament Announced with General Retired David Petraeus as Guest of Honor • Nationally Syndicated “The Bert Show” Hosts Candid Interview with Usher, Who Credits Top Morning-Drive Radio Intervi • The UAE’s Largest Higher Education Institution, Higher Colleges of Technology, Selects YuJa Video Platform to Serve More t • Dr. Laurie Leshin, Director of JPL, to Receive THE MUSES of the California Science Center Foundation 2024 Woman of the Year Awar • Dr. Cathleen Brown Named Medical Director of Winona, Pioneering Menopause Telehealth Company • Yom HaAliyah: The International Fellowship of Christians and Jews Celebrates Helping Thousands of Jews Make Aliyah in 2023 • Canada brings the world together in pursuit of an ambitious global deal to end plastic pollution • Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disor • Innovafeed Expands to U.S.; French Agtech Firm Opens Insect Innovation Center in Decatur, Ill. • RepTrak Announces 2024 Global RepTrak® 100 Report • Franklin Covey Announces New Common Share Purchase Plan • CF Industries Holdings, Inc. Declares Quarterly Dividend and Confirms Dates for First Quarter 2024 Results and Conference Call • WK Kellogg Co and Meijer Donate $50,000 to Battle Creek Public Schools Mission Tiger

KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After Opening

GENEVA , March 21 /Businesswire/ - KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced that late in 2022, it successfully released its inaugural First In Human (FIH) manufacturing batch in compliance with current Good Manufacturing Practice (cGMP) standards in its recently expanded Geneva mammalian cell manufacturing facility. The swift execution of this important milestone demonstrates the capabilities in cell line development (CLD) and biologics manufacturing of KBI and Selexis, allowing clients to accelerate clinical research timelines.

In July 2022, KBI and Selexis announced the completion of the fully integrated, 8,733 square-meter site combining Selexis’ Cell Line Development services and KBI’s development and manufacturing services. This milestone comes only five months after starting operations at the combined facility.

“Delivering this first batch affirms KBI’s commitment to helping pharmaceutical and biotechnology companies across the world achieve their manufacturing goals,” said Mike Landau, Chief Operating Officer of KBI and Selexis. “KBI and Selexis are leading CDMO and cell line development partners, supporting researchers in their efforts to provide groundbreaking therapies for patients in need.”

“ProMIS Neuroscience had a great experience with the Geneva KBI team in developing the process and producing cGMP clinical trial drug substance on time. The KBI team consistently collaborated with ProMIS in an integrated and strategic manner that produced the drug substance with the required quality attributes and exceeded expectations on yield. We are looking forward to our next engagement,” said Gavin Malenfant, Chief Operating Officer of ProMIS Neurosciences Incorporated.

The Geneva KBI and Selexis facility features integrated services including CLD services, analytical formulation services and clinical manufacturing, all under one roof. KBI and Selexis partner with biopharma leaders in developing treatments for a variety of therapeutic areas.

About KBI Biopharma, Inc.

KBI Biopharma, Inc., a JSR Life Sciences company, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.

About Selexis SA

Selexis SA, a JSR Life Sciences company, is a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. As part of a comprehensive drug development process, Selexis technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.